Smart-Money SignalNeutral · 49/100— Insiders are net buyers over 90 days ($22K, 4 buys vs 1 sale)
Net Income-$4.6M
EPS$-0.05
Market Cap$95.6M
Price Performance
Historical data including institutional events
Company Profile
L
Lisa Ricciardi
CEO & Executive Director
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimerâs disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.
Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
